Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CASP9
REST API REST API
Homo sapiens
CASP9 is differentially expressed in 286 experiments: 137 organism parts: kidney, lung, ... (135 more);, 197 disease states: normal, breast carcinoma, ... (195 more);, 107 cell types 331 cell lines 40 compound treatments and 80 other conditions.
Synonyms ICE-LAP6, APAF-3, MCH6
Orthologs F6YWD6_CIOIN (Ciona intestinalis)   casp9 (Danio rerio)   Dcp-1 (Drosophila melanogaster)   Casp9 (Mus musculus)   F1NL59_CHICK (Gallus gallus)   decay (Drosophila melanogaster)   Ice (Drosophila melanogaster)   CASP9 (Bos taurus)   Casp9 (Rattus norvegicus)   casp9 (Xenopus laevis)   Q45T68_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term response to UV, cytosol, protein binding, apoptosis, intracellular, peptidase activity, activation of caspase activity, activation of caspase activity by cytochrome c, fibroblast growth factor receptor signaling pathway, soluble fraction, cysteine-type endopeptidase activity, nucleus, enzyme activator activity, proteolysis, response to DNA damage stimulus, cysteine-type peptidase activity, regulation of apoptosis, apoptosome, induction of apoptosis by intracellular signals, cellular response to dexamethasone stimulus, nerve growth factor receptor signaling pathway, positive regulation of neuron apoptosis, phosphatidylinositol-mediated signaling
InterPro Term Pept_C14_p10, Pept_C14_ICE_p20, Pept_C14_p45_core, Pept_C14_cat, Caspase_IL-1_beta, CARD
UniProt Accession P55211, B4E1A3, Q59GG2, Q5JRU8, Q5JRU2, Q5JRU3, E9PCV5, F8VWA5, F8VVS7
Search EB-eye ENSG00000132906
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-22541, E-GEOD-6573, E-GEOD-3526, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (39 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-5823, E-GEOD-20081, E-GEOD-19639
HL-60
2
E-MTAB-37, E-GEOD-24147
SW1990
1
E-MTAB-37
gmo8398c, fibroblast cell line
1
E-MTAB-62
MV4-11
1
E-MEXP-2170
NCIH1703
1
E-MTAB-37
325 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-MEXP-750, E-GEOD-20677, E-GEOD-2822, ... (52 experiments)

Factor Value U/D Experiments
721 B lymphoblast
2
2
E-AFMX-5, E-TABM-145
2
2
E-TABM-145, E-TABM-130
epithelial cell
1
2
E-GEOD-4483, E-GEOD-10797, E-MEXP-2034
purified CLL B cells from peripheral blood
1
E-GEOD-22529
CD34 positive
1
E-GEOD-12662
primary human mammary epithelial cells
1
E-GEOD-29119
101 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-MTAB-62, E-GEOD-5418, ... (57 experiments)

Factor Value U/D Experiments
rhabdomyosarcoma
2
E-MTAB-37, E-MTAB-62
osteosarcoma
2
E-MTAB-62, E-MTAB-37
colon carcinoma
2
E-MTAB-62, E-MTAB-37
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
cervical carcinoma
1
2
E-MTAB-62, E-MTAB-37, E-GEOD-5823
anaplastic large cell lymphoma
1
E-GEOD-6338
191 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-3720, ... (29 experiments)

Factor Value U/D Experiments
none
4
10
E-TABM-782, E-MEXP-1958, E-GEOD-412, E-GEOD-2803, E-GEOD-2649, ... (14 experiments)
glutamine
2
E-MEXP-941, E-MEXP-1335
lipopolysaccharide
1
2
E-MEXP-1958, E-GEOD-3720, E-TABM-868
ox-LDL
1
E-GEOD-5741
ZMYM2/FGFR1
1
E-GEOD-15811
nocodazole
1
E-GEOD-6431
34 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, E-GEOD-1725 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21374, E-GEOD-2034, ... (9 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-4667, E-MEXP-2283, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-TABM-147, E-GEOD-21138, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MTAB-108, ... (6 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, E-MEXP-421, E-GEOD-22593, ... (12 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-TABM-127, E-GEOD-20540, E-GEOD-20504, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-1926, E-TABM-15, E-GEOD-20876, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-17400 ... (5 experiments)

Initial distant metastases
studied in E-GEOD-22541

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-21750, E-GEOD-6434, E-GEOD-1460, E-GEOD-17636

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Test result
studied in E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, E-GEOD-19246, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-22541, E-GEOD-4922, ... (6 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.331 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM